Generex Announces Conference Call with Members of Generex Oral-lyn™ and Diabetes Program Team

Conference to feature recent advances in Generex Oral-lyn™ development and planned broadening of the Generex Diabetes Program

Jul 08, 2013, 09:15 ET from Generex Biotechnology Corporation

WORCESTER, Mass. and TORONTO, July 8, 2013 /PRNewswire/ -- Generex Biotechnology Corporation ( (OTCBB: GNBT) today announced that it will be hosting a conference call featuring members of its Generex Oral-lyn™ and Diabetes Program Team.  The conference call will focus on recent developments in the global Generex Oral-lyn™ buccal insulin spray program, the planned Generex Oral-lyn™ formulation and process improvements, and the go-forward strategy for the expansion of the Generex Diabetes Program, to include diagnostics and therapeutics for type 1 and type 2 patients as well as pre-diabetes, and potential therapeutics for reducing the complications of diabetes.

The conference call will take place in the context of soon-to-be-announced results of the Shreya Life Sciences Pvt. Ltd. Indian Phase III trial of the product in patients with type 2 diabetes, which results are the basis of Shreya's application for governmental approval of the commercial marketing and sale of the product, known as Oral Recosulin®, in India.

The conference call will take place in September of 2013 and panelists will take questions from callers.  The date and time of the conference call, call-in particulars, agenda, and participating panelists will be announced in the coming weeks.

"We are pleased to be hosting this call to update the investor community on the progress and plans within the Generex Diabetes Program," commented Mark Fletcher, Generex President & Chief Executive Officer.  "As the epidemic of diabetes continues to grow globally, significantly impacting the lives of millions of people and putting severe strain on healthcare resources worldwide, new advances in the prevention, diagnosis and treatment of all types of diabetes and its complications are of critical importance."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at "" or the Antigen Express website at ""

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


SOURCE Generex Biotechnology Corporation